Aft Pharmaceuticals (ASX:AFP)
ASX announcement history & article coverage
Transparent by design.
Announcments by Aft Pharmaceuticals (ASX:AFP) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Results of Meeting
AFT Chair David Flacks to retire before the next ASM
Annual Meeting Presentation 2026
Chair's Address to Shareholders
AFT R&D portfolio offers multi-$bn dollar market potential
AFT R&D portfolio offers multi-$bn market potential
Pitt St Research initiates coverage on AFT Pharmaceuticals
Scomara Tentative Approval by US FDA
AFT Pharmaceuticals receives US FDA tentative approval for Scomara with US launch delayed until 2029
AFT reports ongoing sales growth and R&D progress
Notice of Annual Meeting of Shareholders 2026
Update - Dividend/Distribution - AFP
AFT Pharmaceuticals updates dividend details for FY2026 with unfranked ordinary and supplementary dividends
FDA allows AFT injectable iron project clinical study
FDA approves AFT Pharmaceuticals' injectable iron Phase III clinical trial
FDA allows AFT injectable iron project clinical study
AFT Pharmaceuticals FY26 revenue up 22%, targets $300M+ in FY27 with strong global expansion and R&D pipeline
Application for quotation of securities - AFP
Capital Change Notice